 CAMBRIDGE, Mass., Jan. 05, 2022 GLOBE NEWSWIRE -- Werewolf Therapeutics, Inc. the Company or Werewolf Nasdaq: HOWL, an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the bodys immune system for the treatment of cancer, today announced that management will present at the H.C. Wainwright Bioconnect Conference, taking place virtually from January 10-13, 2022. 